Enzymatica enters into partnership agreement with STADA Arzneimittel which grants STADA exclusive rights to sell, market and distribute Enzymatica’s common cold product ColdZyme in Germany.
Stada is a global pharmaceutical company, headquartered in Germany, with a strong presence in Europe and leading positions in the cough and cold category in Germany, UK, and Russia.
“We are very pleased to have signed the agreement with STADA as our marketing, sales, and distribution partner for Germany, particularly since Germany is the single largest market for over-the-counter products in Europe. This agreement confirms the commercial potential for ColdZyme outside of Scandinavia, and endorses the interest in Enzymatica’s technology platform”, says Fredrik Lindberg, CEO of Enzymatica.
“We are very excited about our agreement with Enzymatica to help maximize the ColdZyme opportunity in Germany. ColdZyme’s unique product offering is different to traditional cold therapies and is a perfect fit to our existing portfolio as well as to our strategy of growing our branded business on the back of launching innovative, new products”, says Wolfram Gollin, Head of Marketing STADA GmbH.